Tags

Type your tag names separated by a space and hit enter

Brucellar reproductive system injury: A retrospective study of 22 cases and review of the literature.
J Int Med Res. 2020 Jun; 48(6):300060520924548.JI

Abstract

OBJECTIVE

We aimed to describe the clinical characteristics and prognosis of 22 patients with Brucella-induced reproductive system injury.

METHODS

We assessed 22 patients with reproductive system injury between 2010 and 2018 at The First Affiliated Hospital of Xinjiang Medical University.

RESULTS

The disease is predominant in men. Male patients had orchitis, erectile dysfunction, prostatitis, and urethral stricture, while female patients had vaginitis and cervicitis. Some patients had laboratory abnormalities and liver injury. Patients received combination therapy of rifampicin and doxycycline. Doxycycline combined with levofloxacin or moxifloxacin was administered to patients with rifampicin intolerance. All patients had received antibiotic therapy for at least 6 weeks. One patient was lost to follow-up, one patient relapsed because of osteoarthropathy, and one patient had dysuria resulting from chronic prostatitis. The clinical symptoms resolved in the other patients, and the overall patient prognosis was good.

CONCLUSION

Clinicians should pay attention to brucellosis-induced reproductive system damage. The two-drug regimen of rifampicin+doxycycline is recommended for these patients. Doxycycline combined with levofloxacin or moxifloxacin should be used in patients with brucellosis-induced reproductive system damage who have rifampicin intolerance. The treatment course should be at least 6 weeks.

Authors+Show Affiliations

Department of Infection Disease Center, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China.The First Hospital of Shihezi University, Shihezi, Xinjiang, China.Department of Infection Disease Center, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China.Department of Infection Disease Center, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China.Department of Infection Disease Center, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China.The First Hospital of Shihezi University, Shihezi, Xinjiang, China.Department of Immunology, Basic Medical College, Xinjiang Medical University, Urumqi, China.Department of Infection Disease Center, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China. Department of Immunology, Basic Medical College, Xinjiang Medical University, Urumqi, China.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32552113

Citation

Zhou, Yan, et al. "Brucellar Reproductive System Injury: a Retrospective Study of 22 Cases and Review of the Literature." The Journal of International Medical Research, vol. 48, no. 6, 2020, p. 300060520924548.
Zhou Y, Xie S, Zheng R, et al. Brucellar reproductive system injury: A retrospective study of 22 cases and review of the literature. J Int Med Res. 2020;48(6):300060520924548.
Zhou, Y., Xie, S., Zheng, R., Dai, Q., Xu, Z., Zuo, W., Ding, J., & Zhang, Y. (2020). Brucellar reproductive system injury: A retrospective study of 22 cases and review of the literature. The Journal of International Medical Research, 48(6), 300060520924548. https://doi.org/10.1177/0300060520924548
Zhou Y, et al. Brucellar Reproductive System Injury: a Retrospective Study of 22 Cases and Review of the Literature. J Int Med Res. 2020;48(6):300060520924548. PubMed PMID: 32552113.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Brucellar reproductive system injury: A retrospective study of 22 cases and review of the literature. AU - Zhou,Yan, AU - Xie,Songsong, AU - Zheng,Rongjiong, AU - Dai,Qinqi, AU - Xu,Zheng, AU - Zuo,Weize, AU - Ding,Jianbing, AU - Zhang,Yuexin, PY - 2020/6/20/entrez PY - 2020/6/20/pubmed PY - 2020/6/20/medline KW - Brucellosis KW - clinical features KW - doxycycline KW - levofloxacin KW - moxifloxacin KW - reproductive system KW - rifampicin intolerance SP - 300060520924548 EP - 300060520924548 JF - The Journal of international medical research JO - J. Int. Med. Res. VL - 48 IS - 6 N2 - OBJECTIVE: We aimed to describe the clinical characteristics and prognosis of 22 patients with Brucella-induced reproductive system injury. METHODS: We assessed 22 patients with reproductive system injury between 2010 and 2018 at The First Affiliated Hospital of Xinjiang Medical University. RESULTS: The disease is predominant in men. Male patients had orchitis, erectile dysfunction, prostatitis, and urethral stricture, while female patients had vaginitis and cervicitis. Some patients had laboratory abnormalities and liver injury. Patients received combination therapy of rifampicin and doxycycline. Doxycycline combined with levofloxacin or moxifloxacin was administered to patients with rifampicin intolerance. All patients had received antibiotic therapy for at least 6 weeks. One patient was lost to follow-up, one patient relapsed because of osteoarthropathy, and one patient had dysuria resulting from chronic prostatitis. The clinical symptoms resolved in the other patients, and the overall patient prognosis was good. CONCLUSION: Clinicians should pay attention to brucellosis-induced reproductive system damage. The two-drug regimen of rifampicin+doxycycline is recommended for these patients. Doxycycline combined with levofloxacin or moxifloxacin should be used in patients with brucellosis-induced reproductive system damage who have rifampicin intolerance. The treatment course should be at least 6 weeks. SN - 1473-2300 UR - https://www.unboundmedicine.com/medline/citation/32552113/Brucellar_reproductive_system_injury:_A_retrospective_study_of_22_cases_and_review_of_the_literature L2 - https://journals.sagepub.com/doi/10.1177/0300060520924548?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.